Recent Developments in the Treatment of Diabetes Type 2

  • Jan O. Nehlin


Diabetes type 2 (T2DM) is a life-long metabolic disease that develops commonly in adulthood as a consequence of an unhealthy life style and genetic predisposition. T2DM is the most common form of diabetes, resulting from both insulin resistances in target organs and insufficient insulin production from pancreas beta cells. T2DM is characterized by increased plasma glucose and insulin levels as well as dyslipidemia. If left untreated chronic diseases will develop that result in a higher mortality risk. ∈dent The prevalence of type 2 diabetes worldwide has increased dramatically in recent times in part due to changes in diet and physical activity levels. Also, several genes underlying monogenic forms of diabetes as well as polymorphic variants have been identified that can contribute to the etiology of the disease. ∈dent A number of treatment strategies exist for T2DM that tackle several of the symptoms. Anti-obesity drugs and PPAR agonists are likely to become efficient pharmacological remedies to prevent further health problems in individuals with T2DM


diabetes type 2 obesity hyperinsulinemia dyslipidemia hyperglycemia PPAR agonists thiazolidinediones 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Abdelrahman, M., Sivarajah, A. and Thiemermann, C. (2005) Beneficial effects of PPAR-gamma ligands in ischemia-reperfusion injury, inflammation and shock. Cardiovasc. Res., 65(4): 772–781.PubMedCrossRefGoogle Scholar
  2. Anderson, D.C., Jr. (2005) Pharmacologic prevention or delay of type 2 diabetes mellitus. Ann. Pharmacother., 39(1): 102–109.PubMedGoogle Scholar
  3. Anderson, J.W. (2006) Diabetes mellitus: medical nutrition therapy. In: Shils, M.E., Shike, M., Ross, C.A., Caballero, B. and Cousins, R.J. eds. (2006) Modern nutrition in health and disease. 10th ed. Lippincott, Williams & Wilkins. 2069 pp.Google Scholar
  4. Asakawa, A., Inui, A., Kaga, T., Katsuura, G., Fujimiya, M., Fujino, M.A. and Kasuga, M. (2003) Antagonism of ghrelin receptor reduces food intake and body weight gain in mice. Gut. 52(7): 947–952.PubMedCrossRefGoogle Scholar
  5. Asfaha, S. and Padwal, R. (2005) Antihypertensive drugs and incidence of type 2 diabetes: evidence and implications for clinical practice. Curr. Hypertens. Rep., 7(5): 314–322.PubMedGoogle Scholar
  6. Atkins, R.C. (2001) Age-defying diet. St. Martin’s paperbacks.Google Scholar
  7. Auwerx, J. (2006) Improving metabolism by increasing energy expenditure. Nat. Med., 12: 44–45.PubMedCrossRefGoogle Scholar
  8. Barroso, I. (2005) Complex disease: pleiotropic gene effects in obesity and type 2 diabetes. Eur J Hum Genet., 13(12): 1243–1244.PubMedCrossRefGoogle Scholar
  9. Bays, H.E. (2004) Current and investigational antiobesity agents and obesity therapeutic treatment targets. Obes. Res., 12(8): 1197–1211.PubMedCrossRefGoogle Scholar
  10. Bedu, E., Wahli, W. and Desvergne, B. (2005) Peroxisome proliferator-activated receptor beta/delta as a therapeutic target for metabolic diseases. Expert Opin. Ther. Targets, 9(4): 861–873.PubMedCrossRefGoogle Scholar
  11. Berger, J.P., Akiyama, T.E. and Meinke, P.T. (2005) PPARs: therapeutic targets for metabolic disease. Trends Pharmacol. Sci., 26(5): 244–251.PubMedCrossRefGoogle Scholar
  12. CDC, Centers for disease control and prevention, USA, 2006. defining.htmGoogle Scholar
  13. Corton, J.C. and Brown-Borg, H.M. (2005) Peroxisome Proliferator-Activated Receptor {gamma} Coactivator 1 in Caloric Restriction and Other Models of Longevity. J Gerontol A Biol Sci Med Sci., 60(12): 1494–1509.PubMedGoogle Scholar
  14. Cox, S.L. (2005) Muraglitazar: an agent for the treatment of type 2 diabetes and associated dyslipidemia. Drugs Today (Barc)., 41(9): 579–587.CrossRefGoogle Scholar
  15. Cunard, R. (2005) The potential use of PPARalpha agonists as immunosuppressive agents. Curr. Opin. Investig. Drugs, 6: 467–472.PubMedGoogle Scholar
  16. de Luca, C. and Olefsky, J.M. (2006) Stressed out about obesity and insulin resistance. Nat. Med., 12(1): 41–42.PubMedCrossRefGoogle Scholar
  17. Despres, J.P., Golay, A., Sjostrom, L., Rimonabant in Obesity-Lipids Study Group (2005) Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N. Engl. J. Med., 353(20): 2121–2134.Google Scholar
  18. Diabetes Prevention Program Research Group (2005) Strategies to identify adults at high risk for type 2 diabetes: the Diabetes Prevention Program. Diabetes Care, 28(1): 138–144.Google Scholar
  19. Durant, N. and Cox, J. (2005) Current treatment approaches to overweight in adolescents. Curr. Opin. Pediatr., 17(4): 454–459.PubMedCrossRefGoogle Scholar
  20. Dwyer, J.T., Allison, D.B. and Coates, P.M. (2005) Dietary supplements in weight reduction. J. Am. Diet Assoc., 105(5 Suppl 1): S80–86.PubMedCrossRefGoogle Scholar
  21. English, P. and Williams, G. (2001) Type 2 diabetes. Martin Dunitz Ltd. 103 pp.Google Scholar
  22. Erion, M.D., van Poelje, P.D., Dang, Q., Kasibhatla, S.R., Potter, S.C., Reddy, M.R., Reddy, K.R., Jiang, T. and Lipscomb, W.N. (2005) MB06322 (CS-917): A potent and selective inhibitor of fructose 1,6-bisphosphatase for controlling gluconeogenesis in type 2 diabetes. Proc. Natl. Acad. Sci. USA, 102(22): 7970–7975.PubMedCrossRefGoogle Scholar
  23. Etgen, G.N. and Mantlo, N. (2003) PPAR ligands for metabolic disorders. Curr. Top. Med. Chem., 3: 1649–1661.PubMedCrossRefGoogle Scholar
  24. Evans, R.M., Barish, G.D. and Wang, Y.X. (2004) PPARs and the complex journey to obesity. Nat. Med., 10: 355–361.PubMedCrossRefGoogle Scholar
  25. Fajas, L., Debril, M.-B. and Auwerx, J. (2001) PPARγ: An essential role in metabolic control. Nutr. Metab. Cardiovasc. Dis., 11: 64–69.PubMedGoogle Scholar
  26. FDA, Federal drug administration, 2006. http://www.fda.govGoogle Scholar
  27. Feinstein, D.L., Spagnolo, A., Akar, C., Weinberg, G., Murphy, P., Gavrilyuk, V. and Russo, C.D. (2005) Receptor-independent actions of PPAR thiazolidinedione agonists: is mitochondrial function the key? Biochem Pharmacol., 70(2): 177–188.PubMedCrossRefGoogle Scholar
  28. Ferre, P. (2004) The biology of peroxisome proliferator-activated receptors: relationship with lipid metabolism and insulin sensitivity. Diabetes, 53 Suppl 1: S43–S50.PubMedCrossRefGoogle Scholar
  29. Filippatos, T.D., Kiortsis, D.N., Liberopoulos, E.N., Mikhailidis, D.P. and Elisaf, M.S. (2005a) A review of the metabolic effects of sibutramine. Curr. Med. Res. Opin., 21(3): 457–468.CrossRefGoogle Scholar
  30. Filippatos, T.D., Kiortsis, D.N., Liberopoulos, E.N., Georgoula, M., Mikhailidis, D.P., Elisaf, M.S. (2005b) Effect of orlistat, micronised fenofibrate and their combination on metabolic parameters in overweight and obese patients with the metabolic syndrome: the FenOrli study. Curr. Med. Res. Opin., 21(12): 1997–2006.CrossRefGoogle Scholar
  31. Fredenrich, A. and Grimaldi, P.A. (2005) PPARdelta: an uncompletely known PPAR nuclear receptor. Diabetes Metab., 31: 23–27.PubMedCrossRefGoogle Scholar
  32. Friedman, M. and McLellan, A. (2006) Healing diabetes: complementary naturopathic and drug treatments. Ccnm press. 272 pp.Google Scholar
  33. Fu, J., Gaetani, S., Oveisi, F., Lo Verme, J., Serrano, A., Rodriguez De Fonseca, F., Rosengarth, A., Luecke, H., Di Giacomo, B., Tarzia, G. and Piomelli, D. (2003) Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-alpha. Nature, 425: 90–93.PubMedCrossRefGoogle Scholar
  34. Gallwitz, B. (2005) Glucagon-like peptide-1-based therapies for the treatment of type 2 diabetes mellitus. Treat Endocrinol., 4(6): 361–370.PubMedCrossRefGoogle Scholar
  35. Gauthier, B.R. and Wollheim, C.B. (2006) MicroRNAs: ‘ribo-regulators’ of glucose homeostasis. Nat. Med., 12: 36–38.PubMedCrossRefGoogle Scholar
  36. Gloyn, A.L. (2003) Glucokinase (GCK) mutations in hyper- and hypoglycemia: maturity-onset diabetes of the young, permanent neonatal diabetes, and hyperinsulinemia of infancy. Hum. Mutat., 22(5): 353–362.PubMedCrossRefGoogle Scholar
  37. Hakim, N., Stratta, R. and Gray, D. (eds.) (2002) Pancreas and islet transplantation. Oxford Univ. Press. 378 pp.Google Scholar
  38. Hammarstedt, A., Andersson, C.X., Rotter Sopasakis, V. and Smith, U. (2005) The effect of PPARgamma ligands on the adipose tissue in insulin resistance. Prostaglandins Leukot. Essent. Fatty Acids., 73(1): 65–75.CrossRefGoogle Scholar
  39. Hansen, L. and Pedersen, O. (2005) Genetics of type 2 diabetes mellitus: status and perspectives. Diabetes Obes. Metab., 7(2): 122–135.PubMedCrossRefGoogle Scholar
  40. Harrity, T., Farrelly, D., Tieman, A., Chu, C., Kunselman, L., Gu, L., Ponticiello, R., Cap, M., Qu, F., Shao, C., Wang, W., Zhang, H., Fenderson, W., Chen, S., Devástale, P., Jeon, Y., Seethala, R., Yang, W.P., Ren, J., Zhou, M., Ryono, D., Biller, S., Mookhtiar, K.A., Wetterau, J., Gregg, R., Cheng, P.T. and Hariharan, N. (2006) Muraglitazar, a novel dual ({alpha}/{gamma}) Peroxisome Proliferator-Activated Receptor activator, improves diabetes and other metabolic abnormalities and preserves {beta}-Cell Function in db/db mice. Diabetes, 55(1): 240–248.PubMedCrossRefGoogle Scholar
  41. Hauner, H. (2004) Managing type 2 diabetes mellitus in patients with obesity. Treat Endocrinol., 3(4): 223–232.PubMedCrossRefGoogle Scholar
  42. Hill, J.O., Catenacci, V.A. and Wyatt, H.R. (2006). Obesity: etiology. Chapter 63. pp 1013–1028. In Shils, M.E., Shike, M., Ross, C.A., Caballero, B. and Cousins, R.J. (eds.) (2006) Modern nutrition in health and disease. 10th ed. Lippincott, Williams and Wilkins.2069 pp.Google Scholar
  43. Hoivik, D.J., Qualls, C.W. Jr, Mirabile, R.C., Cariello, N.F., Kimbrough, C.L., Colton, H.M., Anderson, S.P., Santostefano, M.J., Morgan, R.J., Dahl, R.R., Brown, A.R., Zhao, Z., Mudd, P.N. Jr, Oliver, W.B. Jr, Brown, H.R. and Miller, R.T. (2004) Fibrates induce hepatic peroxisome and mitochondrial proliferation without overt evidence of cellular proliferation and oxidative stress in cynomolgus monkeys. Carcinogenesis, 25(9): 1757–1769.PubMedCrossRefGoogle Scholar
  44. Hovens, M.M., Tamsma, J.T., Beishuizen, E.D. and Huisman, M.V. (2005) Pharmacological strategies to reduce cardiovascular risk in type 2 diabetes mellitus: an update. Drugs, 65(4): 433–445.PubMedCrossRefGoogle Scholar
  45. Jiang, G. and Zhang, B.B. (2005) Modulation of insulin signalling by insulin sensitizers. Biochem. Soc. Trans., 33(Pt 2): 358–361.Google Scholar
  46. Kadowaki, T. and Yamauchi, T. (2005) Adiponectin and adiponectin receptors. Endocr. Rev., 26(3): 439–451.PubMedCrossRefGoogle Scholar
  47. Kahn, C.R., Weir, G.C., King, G.L., Jacobson, A.M., Moses, A.C. and Smith, R.J. (eds.) (2005) Joslin’s diabetes mellitus, 14th ed. Lippincott Williams and Wilkins. 1209 pp.Google Scholar
  48. Kaplan, L.H. (2005) Pharmacological therapies for obesity. Gastroenterol. Clin. North Am., 34(1): 91–104.Google Scholar
  49. Karanam, M., Song, Z. and Jindal, R.M. (2002) Gene therapy for diabetes. Chapter 21. 291–304. In Hakim, N., Stratta, R. and Gray, D. (eds.) Pancreas and islet transplantation. Oxford Univ. Press. 378 pp.Google Scholar
  50. Kim, S.H., Hyun, S.H. and Choung, S.Y. (2006) Anti-diabetic effect of cinnamon extract on blood glucose in db/db mice. J. Ethnopharmacol. In press.Google Scholar
  51. Kiortsis, D.N., Filippatos, T.D. and Elisaf, M.S. (2005) The effects of orlistat on metabolic parameters and other cardiovascular risk factors. Diabetes Metab., 31(1): 15–22.PubMedCrossRefGoogle Scholar
  52. Kojima, I. and Umezawa, K. (2006) Conophylline: A novel differentiation inducer for pancreatic beta cells. Int. J. Biochem. Cell. Biol., In press.Google Scholar
  53. Kota, B.P., Huang, T.H. and Roufogalis, B.D. (2005) An overview on biological mechanisms of PPARs. Pharmacol. Res., 51(2): 85–94.PubMedCrossRefGoogle Scholar
  54. Kubota, N., Terauchi, Y., Miki, H., Tamemoto, H., Yamauchi, T., Komeda, K., Satoh, S., Nakano, R., Ishii, C., Sugiyama, T., Eto, K., Tsubamoto, Y., Okuno, A., Murakami, K., Sekihara, H., Hasegawa, G., Naito, M., Toyoshima, Y., Tanaka, S., Shiota, K., Kitamura, T., Fujita, T., Ezaki, O., Aizawa, S., Kadowaki, T. et al. (1999) PPAR gamma mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance. Mol. Cell, 4(4): 597–609.PubMedCrossRefGoogle Scholar
  55. Kulkarni, R.N. (2004) The islet β-cell. Int. J. Biochem. Cell Biol. 36: 365–371.PubMedCrossRefGoogle Scholar
  56. Kurtz, T.W. and Pravenec, M. (2004) Antidiabetic mechanisms of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists: beyond the renin-angiotensin system. J. Hypertens., 22(12): 2253–2261.PubMedCrossRefGoogle Scholar
  57. Kusminski, C.M., McTernan, P.G. and Kumar, S. (2005) Role of resistin in obesity, insulin resistance and Type II diabetes. Clin Sci (Lond)., 109(3): 243–256.CrossRefGoogle Scholar
  58. Laakso, M. (2005) Prevention of type 2 diabetes. Curr Mol Med., 5(3): 365–374.PubMedCrossRefGoogle Scholar
  59. Lazar, M.A. (2005) PPAR gamma, 10 years later. Biochimie, 87(1): 9–13.PubMedCrossRefGoogle Scholar
  60. Lebovitz, H.E. (2005) Management of hyperglycemia with oral antihyperglycemic agents in type 2 diabetes. Chapter 41.687–710. In: Kahn, C.R., Weir, G.C., King, G.L., Jacobson, A.M., Moses, A.C. and Smith, R.J. (eds.) (2005) Joslin’s diabetes mellitus, 14th ed. Lippincott Williams & Wilkins. 1209 pp.Google Scholar
  61. List, J.F. and Habener, J.F. (2004) Glucagon-like peptide 1 agonists and the development and growth of pancreatic beta-cells. Am. J. Physiol. Endocrinol. Metab., 286(6), E875–E881.Google Scholar
  62. Lo Verme, J., Gaetani, S., Fu, J., Oveisi, F., Burton, K. and Piomelli, D. (2005) Regulation of food intake by oleoylethanolamide. Cell. Mol. Life Sci., 62(6): 708–716.PubMedCrossRefGoogle Scholar
  63. Lowell, B.B. and Shulman, G.I. (2005) Mitochondrial dysfunction and type 2 diabetes. Science, 307(5708): 384–387.PubMedCrossRefGoogle Scholar
  64. Luquet, S., Lopez-Soriano, J., Holst, D., Fredenrich, A., Melki, J., Rassoulzadegan, M. and Grimaldi, P.A. (2003) Peroxisome proliferator-activated receptor delta controls muscle development and oxidative capability. FASEB J., 17(15): 2299–2301.PubMedGoogle Scholar
  65. Luquet, S., Gaudel, C., Holst, D., Lopez-Soriano, J., Jehl-Pietri, C., Fredenrich, A. and Grimaldi, P.A. (2005) Roles of PPAR delta in lipid absorption and metabolism: a new target for the treatment of type 2 diabetes. Biochim. Biophys. Acta, 1740(2): 313–317.PubMedGoogle Scholar
  66. Malecki, M.T. (2005) Genetics of type 2 diabetes mellitus. Diabetes Res. Clin. Pract., 68 Suppl1: S10–S21.Google Scholar
  67. Mathys, M. (2005) Pharmacologic agents for the treatment of obesity. Clin. Geriatr. Med., 21(4): 735–746.PubMedCrossRefGoogle Scholar
  68. Mogensen, J.P., Jeppesen, L., Bury, P.S., Pettersson, I., Fleckner, J., Nehlin, J., Frederiksen, K.S., Albrektsen, T., Din, N., Mortensen, S.B., Svensson, L.A., Wassermann, K., Wulff, E.M., Ynddal, L. and Sauerberg, P. (2003) Design and synthesis of novel PPARalpha/gamma/delta triple activators using a known PPARalpha/gamma dual activator as structural template. Bioorg. Med. Chem. Lett., 13: 257–260.PubMedCrossRefGoogle Scholar
  69. Nakamichi, Y., Kikuta, T., Ito, E., Ohara-Imaizumi, M., Nishiwaki, C., Ishida, H. and Nagamatsu, S. (2003) PPAR-gamma overexpression suppresses glucose-induced proinsulin biosynthesis and insulin release synergistically with pioglitazone in MIN6 cells. Biochem. Biophys. Res. Commun., 306(4): 832–836.PubMedCrossRefGoogle Scholar
  70. Nehlin, J.O., Mogensen, J.P., Petterson, I., Jeppesen, L., Fleckner, J., Wulff, E.M. and Sauerberg, P. (2006) Selective PPAR agonists for the treatment of diabetes type 2. Annals N.Y. Acad. Sci. In press.Google Scholar
  71. Oliver, W.R. Jr, Shenk, J.L., Snaith, M.R., Russell, C.S., Plunket, K.D., Bodkin, N.L., Lewis, M.C., Winegar, D.A., Sznaidman, M.L., Lambert, M.H., Xu, H.E., Sternbach, D.D., Kliewer, S.A., Hansen, B.C. and Willson, T.M. (2001) A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport. Proc. Natl. Acad. Sci.USA, 98: 5306–5311.PubMedCrossRefGoogle Scholar
  72. Owen, M.R., Doran, E. and Halestrap, A.P. (2000) Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem J., 348 Pt. 3: 607–614.Google Scholar
  73. Ozcan, U., Cao, Q., Yilmaz, E., Lee, A.H., Iwakoshi, N.N., Ozdelen, E., Tuncman, G., Gorgun, C., Glimcher, L.H. and Hotamisligil, G.S. (2004) Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science, 306(5695): 457–461.PubMedCrossRefGoogle Scholar
  74. Padwal, R., Majumdar, S.R., Johnson, J.A., Varney, J. and McAlister, F.A. (2005) A systematic review of drug therapy to delay or prevent type 2 diabetes. Diabetes Care, 28(3): 736–744.PubMedCrossRefGoogle Scholar
  75. Park, S.Y., Cho, Y.R., Finck, B.N., Kim, H.J., Higashimori, T., Hong, E.G., Lee, M.K., Danton, C., Deshmukh, S., Cline, G.W., Wu, J.J., Bennett, A.M., Rothermel, B., Kalinowski, A., Russell, K.S., Kim, Y.B., Kelly, D.P. and Kim, J.K. (2005) Cardiac-specific overexpression of peroxisome proliferator-activated receptor-alpha causes insulin resistance in heart and liver. Diabetes, 54(9): 2514–2524.PubMedCrossRefGoogle Scholar
  76. Poulsen, M.K., Henriksen, J.E., Hother-Nielsen, O. and Beck-Nielsen, H. (2003) The combined effect of triple therapy with rosiglitazone, metformin, and insulin aspart in type 2 diabetic patients. Diabetes Care, 26(12): 3273–3279.PubMedCrossRefGoogle Scholar
  77. Press, M. (2002) The nature of the problem: why do we need pancreatic transplantation? Chapter 2. In: Hakim, N., Stratta, R. and Gray, D. (eds.) (2002) Pancreas and islet transplantation. Oxford Univ. Press. 378 pp.Google Scholar
  78. Puigserver, P. and Rodgers, J.T. (2006) Foxa2, a novel transcriptional regulator of insulin sensitivity. Nat Med., 12(1): 38–39.PubMedCrossRefGoogle Scholar
  79. Puigserver, P. (2005) Tissue-specific regulation of metabolic pathways through the transcriptional coactivator PGC1-alpha. Int.J.Obes.(Lond), 29 Suppl 1: S5–S9.CrossRefGoogle Scholar
  80. Rangwala, S.M. and Lazar, M.A. (2004) Peroxisome proliferator-activated receptor gamma in diabetes and metabolism. Trends Pharmacol. Sci., 25: 331–336.PubMedCrossRefGoogle Scholar
  81. Reaven, G.M. (2005) The insulin resistance syndrome: definition and dietary approaches to treatment. Annu. Rev. Nutr., 25: 391–406.PubMedCrossRefGoogle Scholar
  82. Rhodes, C.J. (2005) Type 2 diabetes-a matter of beta-cell life and death? Science, 307(5708): 380–384.PubMedCrossRefGoogle Scholar
  83. Ricketts, M.L., Moore, D.D., Banz, W.J., Mezei, O. and Shay, N.F. (2005) Molecular mechanisms of action of the soy isoflavones includes activation of promiscuous nuclear receptors. A review. J. Nutr. Biochem., 16(6): 321–330.CrossRefGoogle Scholar
  84. Rimando, A.M., Nagmani, R., Feller, D.R. and Yokohama, W. (2005) Pterostilbene, a new agonist for the peroxisome proliferator-activated receptor alpha-isoform, lowers plasma lipoproteins and cholesterol in hypercholesterolemic hamsters. J. Agric. Food Chem., 53(9): 3403–3407.PubMedCrossRefGoogle Scholar
  85. Rosen, E.D. and Spiegelman, B.M. (2001) PPARgamma: a nuclear regulator of metabolism, differentiation, and cell Growth. J. Biol. Chem., 276: 37731–37734.PubMedCrossRefGoogle Scholar
  86. Rotella, C.M., Pala, L. and Mannucci, E. (2005) Glucagon-like peptide 1 (GLP-1) and metabolic diseases. J. Endocrinol. Invest., 28(8): 746–758.PubMedGoogle Scholar
  87. Sacerdote, A., Weiss, K., Tran, T., Rokeya Noor, B. and McFarlane, S.I. (2005) Hypertension in patients with Cushing’s disease: pathophysiology, diagnosis, and management. Curr. Hypertens. Rep., 7(3): 212–218.PubMedGoogle Scholar
  88. Saenz, A., Fernandez-Esteban, I., Mataix, A., Ausejo, M., Roque, M. and Moher, D. (2005) Metformin monotherapy for type 2 diabetes mellitus. Cochrane Database Syst. Rev. 3: CD002966.Google Scholar
  89. Sauerberg, P., Pettersson, I., Jeppesen, L., Bury, P.S., Mogensen, J.P., Wassermann, K., Brand, C.L., Sturis, J., Woldike, H.F., Fleckner, J., Andersen, A.S., Mortensen, S.B., Svensson, L.A., Rasmussen, H.B., Lehmann, S.V., Polivka, Z., Sindelar, K., Panajotova, V., Ynddal, L. and Wulff, E.M. (2002) Novel tricyclic-α-alkyloxyphenylpropionic acids: dual PPARalpha/gamma agonists with hypolipidemic and antidiabetic activity. J. Med. Chem., 45: 789–804.PubMedCrossRefGoogle Scholar
  90. Sauerberg, P., Bury, P.S., Mogensen, J.P., Deussen, H.J., Pettersson, I., Fleckner, J., Nehlin, J., Frederiksen, K.S., Albrektsen, T., Din, N., Svensson, L.A., Ynddal, L., Wulff, E.M., and Jeppesen, L. (2003) Large dimeric ligands with favorable pharmacokinetic properties and peroxisome proliferator-activated receptor agonist activity in vitro and in vivo. J. Med. Chem., 46: 4883–4894.PubMedGoogle Scholar
  91. Sauerberg, P., Mogensen, J.P., Jeppesen, L., Svensson, L.A., Fleckner, J., Nehlin, J., Wulff, E.M. and Pettersson, I. (2005) Structure-activity relationships of dimeric PPAR agonists. Bioorg. Med. Chem. Lett., 15: 1497–1500.PubMedCrossRefGoogle Scholar
  92. Scher, J.U. and Pillinger, M.H. (2005) 15d-PGJ2: the anti-inflammatory prostaglandin? Clin. Immunol., 114(2): 100–109.PubMedCrossRefGoogle Scholar
  93. Schulze, M.B. and Hu, F.B. (2005) Primary prevention of diabetes: what can be done and how much can be prevented? Annu. Rev. Public Health, 26: 445–467.CrossRefGoogle Scholar
  94. Scott, R., Best, J., Forder, P., Taskinen, M.R., Simes, J., Barter, P., Keech, A. and FIELD Study Investigators (2005) Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: baseline characteristics and short-term effects of fenofibrate. Cardiovasc Diabetol., 4: 13.Google Scholar
  95. Seeley, R.J. and Tschop, M. (2006) How diabetes went to our heads. Nat Med., 12(1): 47–49.PubMedCrossRefGoogle Scholar
  96. Shils, M.E., Shike, M., Ross, C.A., Caballero, B. and Cousins, R.J. eds. (2006) Modern nutrition in health and disease. 10th ed. Lippincott, Williams and Wilkins. 2069 pp.Google Scholar
  97. Soria, B., Roche, E., Reig, J.A. and Martin, F. (2005) Generation of insulin-producing cells from stem cells. Novartis Found Symp. 265: 158–167; discussion 167–73, 204–11.Google Scholar
  98. Sorkin, J.D., Muller, D.C., Fleg, J.L. and Andres, R. (2005) The relation of fasting and 2-h postchallenge plasma glucose concentrations to mortality: data from the Baltimore Longitudinal Study of Aging with a critical review of the literature. Diabetes Care, 28(11): 2626–2632.PubMedCrossRefGoogle Scholar
  99. Speight, T.M. and Holford, N.H.G. (eds.) (1997) Avery’s drug treatment. 4th ed. Adis International Ltd.Google Scholar
  100. Spiegelman, B.M. and Flier, J.S. (2001) Obesity and the regulation of energy balance. Cell, 104: 531–543.PubMedCrossRefGoogle Scholar
  101. Staels, B. and Fruchart, J.C. (2005) Therapeutic roles of peroxisome proliferator-activated receptor agonists. Diabetes, 54(8): 2460–2470.PubMedCrossRefGoogle Scholar
  102. Staels, B. (2005) PPARgamma and atherosclerosis. Curr. Med. Res. Opin., 21 Suppl 1: S13–S20 (2005).Google Scholar
  103. Steinbeck, K. (2005) Childhood obesity. Treatment options. Best Pract. Res. Clin. Endocrinol. Metab., 19(3): 455–469.CrossRefGoogle Scholar
  104. Stumvoll, M., Goldstein, B.J.. and van Haeften, T.W. (2005) Type 2 diabetes: principles of pathogenesis and therapy. Lancet, 365: 1333–1346.Google Scholar
  105. Sturis, J., Gotfredsen, C.F., Romer, J., Rolin, B., Ribel, U., Brand, C.L., Wilken, M., Wassermann, K., Deacon, C.F., Carr, R.D. and Knudsen, L.B. (2003) GLP-1 derivative liraglutide in rats with beta-cell deficiencies: influence of metabolic state on beta-cell mass dynamics. Br. J. Pharmacol., 140(1): 123–132.PubMedCrossRefGoogle Scholar
  106. Tan, N.S., Michalik, L., Desvergne, B. and Wahli, W. (2005) Multiple expression control mechanisms of peroxisome proliferator-activated receptors and their target genes. J. Steroid Biochem. Mol. Biol., 93(2–5): 99–105.Google Scholar
  107. Tanaka, T., Yamamoto, J., Iwasaki, S., Asaba, H., Hamura, H., Ikeda, Y., Watanabe, M., Magoori, K., Ioka, R.X., Tachibana, K., Watanabe, Y., Uchiyama, Y., Sumi, K., Iguchi, H., Ito, S., Doi, T., Hamakubo, T., Naito, M., Auwerx, J., Yanagisawa, M., Kodama, T. and Sakai, J. (2003) Activation of peroxisome proliferator-activated receptor delta induces fatty acid beta-oxidation in skeletal muscle and attenuates metabolic syndrome. Proc. Natl. Acad. Sci. USA, 100(26): 15924–15929.PubMedCrossRefGoogle Scholar
  108. Taylor, S.I. (1999) Deconstructing type 2 diabetes. Cell, 97: 9–12.PubMedCrossRefGoogle Scholar
  109. Toyoshima, Y., Gavrilova, O., Yakar, S., Jou, W., Pack, S., Asghar, Z., Wheeler, M.B. and LeRoith, D. (2005) Leptin improves insulin resistance and hyperglycemia in a mouse model of type 2 diabetes. Endocrinology, 146(9): 4024–4035.PubMedCrossRefGoogle Scholar
  110. Unger, R.H. (2006) Klotho-induced insulin resistance: a blessing in disguise? Nat. Med., 12(1): 56–57.PubMedCrossRefGoogle Scholar
  111. van Raalte, D.H., Li, M., Pritchard, P.H. and Wasan, K.M. (2004) Peroxisome proliferator-activated receptor (PPAR)-alpha: a pharmacological target with a promising future. Pharm. Res., 21: 1531–1538.PubMedCrossRefGoogle Scholar
  112. Verma, N.K., Singh, J. and Dey, C.S. (2004) PPAR-gamma expression modulates insulin sensitivity in C2C12 skeletal muscle cells. Br. J. Pharmacol., 143(8): 1006–1013.PubMedCrossRefGoogle Scholar
  113. Wadman, M. (2006) Rimonabant adds appetizing choice to slim obesity market. Nat. Med., 12, 27 (2006).Google Scholar
  114. Wang, Y.L., Frauwirth, K.A., Rangwala, S.M., Lazar, M.A. and Thompson, C.B. (2002) Thiazolidinedione Activation of Peroxisome Proliferator-activated Receptor γ Can Enhance Mitochondrial Potential and Promote Cell Survival. J. Biol. Chem., 277: 31781–317888.PubMedCrossRefGoogle Scholar
  115. Wang, Y.X., Lee, C.H., Tiep, S., Yu, R.T., Ham, J., Kang, H. and Evans, R.M. (2003) Peroxisome-Proliferator-activated receptor d activates fat metabolism to prevent obesity. Cell, 113: 159–170.PubMedCrossRefGoogle Scholar
  116. WHO, World Health Organisation. 2006. Scholar
  117. Wild, S., Roglic, G., Green, A., Sicree, R. and King, H. (2004) Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care, 27: 1047–1053.PubMedCrossRefGoogle Scholar
  118. Wild, S., Roglic, G., Green, A., Sicree, R. and King, H. (2004) Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care, 27: 1047–1053.PubMedCrossRefGoogle Scholar
  119. Yach, D., Stuckler, D., and Brownell, K.D. (2006) Epidemiologic and economic consequences of the global epidemics of obesity and diabetes. Nat. Med., 12(1): 62–66.PubMedCrossRefGoogle Scholar
  120. Youssef, J.A. and Badr, M.Z. (2005) Aging and enhanced hepatocarcinogenicity by peroxisome proliferator-activated receptor alpha agonists. Ageing Res. Rev., 4: 103–118.PubMedCrossRefGoogle Scholar
  121. Yu, S., Matsusue, K., Kashireddy, P., Cao, W.Q., Yeldandi, V., Yeldandi, A.V., Rao, M.S., Gonzalez, F.J. and Reddym, J.K. (2003) Adipocyte-specific gene expression and adipogenic steatosis in the mouse liver due to peroxisome proliferator-activated receptor gamma1 (PPARgamma1) overexpression. J. Biol. Chem., 278(1): 498–505.PubMedCrossRefGoogle Scholar
  122. Zhang, J., Fu, M., Cui, T., Xiong, C., Xu, K., Zhong, W., Xiao, Y., Floyd, D., Liang, J., Li, E., Song, Q. and Chen, Y.E. (2004a) Selective disruption of PPARg2 impairs the development of adipose tissue and insulin sensitivity. Proc. Natl. Acad. Sci. USA, 101: 10703–10708.CrossRefGoogle Scholar
  123. Zhang, F., Lavan, B. and Gregoire, F.M. (2004b) Peroxisome proliferator-activated receptors as attractive antiobesity targets. Drug News Perspect., 17(10): 661–669.CrossRefGoogle Scholar
  124. Zingarelli, B. and Cook, J.A. (2005) Peroxisome proliferator-activated receptor-gamma is a new therapeutic target in sepsis and inflammation. Shock, 23(5): 393–399.PubMedCrossRefGoogle Scholar

Copyright information

© Springer 2006

Authors and Affiliations

  • Jan O. Nehlin
    • 1
  1. 1.Department of Clinical ImmunologyOdense University Hospital & University of Southern Denmark5000 Odense

Personalised recommendations